Top

Published in:

Open Access 01-12-2023 | Breast Cancer | Research

Disclosing a metabolic signature of cisplatin resistance in MDA-MB-231 triple-negative breast cancer cells by NMR metabolomics

Authors: Tatiana J. Carneiro, Ana L. M. Batista Carvalho, Martin Vojtek, Inês F. Carmo, Maria Paula M. Marques, Carmen Diniz, Ana M. Gil

Published in: Cancer Cell International | Issue 1/2023

Abstract

This work compared the metabolic profile of a parental MDA-MB-231 cisplatin-sensitive triple negative breast cancer (TNBC) cell line with that of a derived cisplatin-resistant line, to characterize inherent metabolic adaptations to resistance, as a means for marker and new TNBC therapies discovery. Supported by cytotoxic, microscopic and biochemical characterization of both lines, Nuclear Magnetic Resonance (NMR) metabolomics was employed to characterize cell polar extracts for the two cell lines, as a function of time (0, 24 and 48 h), and identify statistically relevant differences both between sensitive and resistant cells and their time course behavior. Biochemical results revealed a slight increase in activation of the NF-κB pathway and a marked decrease of the ERK signaling pathway in resistant cells. This was accompanied by lower glycolytic and glutaminolytic activities, possibly linked to glutamine being required to increase stemness capacity and, hence, higher survival to cisplatin. The TCA cycle dynamics seemed to be time-dependent, with an apparent activation at 48 h preferentially supported by anaplerotic aromatic amino acids, leucine and lysine. A distinct behavior of leucine, compared to the other branched-chain-amino-acids, suggested the importance of the recognized relationship between leucine and in mTOR-mediated autophagy to increase resistance. Suggested markers of MDA-MB-231 TNBC cisplatin-resistance included higher phosphocreatine/creatine ratios, hypotaurine/taurine–mediated antioxidant protective mechanisms, a generalized marked depletion in nucleotides/nucleosides, and a distinctive pattern of choline compounds. Although the putative hypotheses generated here require biological demonstration, they pave the way to the use of metabolites as markers of cisplatin-resistance in TNBC and as guidance to develop therapies.

Available only for authorised users

Zhang J, Xia Y, Zhou X, Yu H, Tan Y, et al. Current landscape of personalized clinical treatments for triple-negative breast cancer. Front Pharmacol. 2022;13:977660. https://doi.org/10.3389/fphar.2022.977660.CrossRefPubMedPubMedCentral

Lucaciu RL, Hangan AC, Sevastre B, Oprean LS. Metallo-drugs in cancer therapy: past. Present and Future Molecules. 2022;27:6485. https://doi.org/10.3390/molecules27196485.CrossRefPubMed

Makovec T. Cisplatin and beyond: molecular mechanisms of action and drug resistance development in cancer chemotherapy. Radiol Oncol. 2019;53:148–58. https://doi.org/10.2478/raon-2019-0018.CrossRefPubMedPubMedCentral

Giaccone G. Clinical perspectives on platinum resistance. Drugs. 2000;59(Suppl 4):9–17. https://doi.org/10.2165/00003495-200059004-00002.CrossRefPubMed

Uno K, Yoshikawa N, Tazaki A, Ohnuma S, Kitami K, et al. Significance of platinum distribution to predict platinum resistance in ovarian cancer after platinum treatment in neoadjuvant chemotherapy. Sci Rep. 2022;12:4513. https://doi.org/10.1038/s41598-022-08503-7.CrossRefPubMedPubMedCentral

D’Amora P, Silva IDCG, Tewari KS, Bristow RE, Cappuccini F, et al. Platinum resistance in gynecologic malignancies: response, disease free and overall survival are predicted by biochemical signature: a metabolomic analysis. Gynecol Oncol. 2021;163:162–70. https://doi.org/10.1016/j.ygyno.2021.08.001.CrossRefPubMed

Bai X, Ni J, Beretov J, Graham P, Li Y. Triple-negative breast cancer therapeutic resistance: where is the Achilles’ heel? Cancer Lett. 2021;497:100–11. https://doi.org/10.1016/j.canlet.2020.10.016.CrossRefPubMed

Ciarimboli G. Membrane transporters as mediators of cisplatin side-effects. Anticancer Res. 2014;34:547–50.PubMed

Chen SH, Chang JY. new insights into mechanisms of cisplatin resistance: from tumor cell to microenvironment. Int J Mol Sci. 2019;20:4136. https://doi.org/10.3390/ijms20174136.CrossRefPubMedPubMedCentral

10.

Zhou J, Kang Y, Chen L, Wang H, Liu J, et al. The drug-resistance mechanisms of five platinum-based antitumor agents. Front Pharmacol. 2020;11:343. https://doi.org/10.3389/fphar.2020.00343.CrossRefPubMedPubMedCentral

11.

Wang L, Zhao X, Fu J, Xu W, Yuan J. The role of tumour metabolism in cisplatin resistance. Front Mol Biosci. 2021;8:691795. https://doi.org/10.3389/fmolb.2021.691795.CrossRefPubMedPubMedCentral

12.

Poisson LM, Munkarah A, Madi H, Datta I, Hensley-Alford S, et al. A metabolomic approach to identifying platinum resistance in ovarian cancer. J Ovarian Res. 2015;8:13. https://doi.org/10.1186/s13048-015-0140-8.CrossRefPubMedPubMedCentral

13.

Ghini V, Magherini F, Massai L, Messori L, Turano P. Comparative NMR metabolomics of the responses of A2780 human ovarian cancer cells to clinically established Pt-based drugs. Dalton Trans. 2022;51:12512–23. https://doi.org/10.1039/d2dt02068h.CrossRefPubMed

14.

Criscuolo D, Avolio R, Parri M, Romano S, Chiarugi P, et al. Decreased levels of GSH are associated with platinum resistance in high-grade serous ovarian cancer. Antioxidants. 2022;11:1544. https://doi.org/10.3390/antiox11081544.CrossRefPubMedPubMedCentral

15.

Acland M, Lokman NA, Young C, Anderson D, Condina M, et al. Chemoresistant cancer cell lines are characterized by migratory, amino acid metabolism, protein catabolism and IFN1 signalling perturbations. Cancers. 2022;14:2763. https://doi.org/10.3390/cancers14112763.CrossRefPubMedPubMedCentral

16.

Galvez L, Rusz M, Schwaiger-Haber M, El Abiead Y, Hermann G, et al. Preclinical studies on metal based anticancer drugs as enabled by integrated metallomics and metabolomics. Metallomics. 2019;11:1716–28. https://doi.org/10.1039/c9mt00141g.CrossRefPubMed

17.

Herrmann HA, Rusz M, Baier D, Jakupec MA, Keppler BK, et al. Thermodynamic genome-scale metabolic modeling of metallodrug resistance in colorectal cancer. Cancers. 2021;13:4130. https://doi.org/10.3390/cancers13164130.CrossRefPubMedPubMedCentral

18.

Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;7:209–49. https://doi.org/10.3322/caac.21660.CrossRef

19.

Demas DM, Demo S, Fallah Y, Clarke R, Nephew KP, et al. Glutamine metabolism drives growth in advanced hormone receptor positive breast cancer. Front Oncol. 2019;9:686. https://doi.org/10.3389/fonc.2019.00686.CrossRefPubMedPubMedCentral

20.

Tomková V, Sandoval-Acuña C, Torrealba N, Truksa J. Mitochondrial fragmentation, elevated mitochondrial superoxide and respiratory supercomplexes disassembly is connected with the tamoxifen-resistant phenotype of breast cancer cells. Free Radic Biol Med. 2019;143:510–21. https://doi.org/10.1016/j.freeradbiomed.2019.09.004.CrossRefPubMed

21.

Barkovskaya A, Seip K, Prasmickaite L, Mills IG, Moestue SA, Itkonen HM. Inhibition of O-GlcNAc transferase activates tumor-suppressor gene expression in tamoxifen-resistant breast cancer cells. Sci Rep. 2020;10:16992. https://doi.org/10.1038/s41598-020-74083-z.CrossRefPubMedPubMedCentral

22.

Pal P, Millner A, Semina SE, Huggins RJ, Running L, et al. Endocrine therapy-resistant breast cancer cells are more sensitive to ceramide kinase inhibition and elevated ceramide levels than therapy-sensitive breast cancer cells. Cancers. 2022;14:2380. https://doi.org/10.3390/cancers14102380.CrossRefPubMedPubMedCentral

23.

Tan Z, Ge C, Feng D, Xu C, Cao B, et al. The Interleukin-6/Signal transducer and activator of transcription-3/Cystathionine γ-lyase axis deciphers the transformation between the sensitive and resistant phenotypes of breast cancer cells. Drug Metab Dispos. 2021;49:985–94. https://doi.org/10.1124/dmd.121.000571.CrossRefPubMed

24.

Barata IS, Gomes BC, Rodrigues AS, Rueff J, Kranendonk M, et al. The complex dynamic of phase i drug metabolism in the early stages of doxorubicin resistance in breast cancer cells. Genes. 2022;13:1977. https://doi.org/10.3390/genes13111977.CrossRefPubMedPubMedCentral

25.

Saha T, Lukong KE. Breast cancer stem-like cells in drug resistance: a review of mechanisms and novel therapeutic strategies to overcome drug resistance. Front Oncol. 2022;12:856974. https://doi.org/10.3389/fonc.2022.856974.CrossRefPubMedPubMedCentral

26.

Maria RM, Altei WF, Selistre-de-Araujo HS, Colnago LA. Impact of chemotherapy on metabolic reprogramming: characterization of the metabolic profile of breast cancer MDA-MB-231 cells using ¹H HR-MAS NMR spectroscopy. J Pharm Biomed Anal. 2017;146:324–8. https://doi.org/10.1016/j.jpba.2017.08.038.CrossRefPubMed

27.

Resendiz-Acevedo K, García-Aguilera ME, Esturau-Escofet N, Ruiz-Azuara L. ¹H -NMR metabolomics study of the effect of cisplatin and Casiopeina iigly on MDA-MB-231 breast tumor cells. Front Mol Biosci. 2021;8:742859. https://doi.org/10.3389/fmolb.2021.742859.CrossRefPubMedPubMedCentral

28.

Geck RC, Foley JR, Murray Stewart T, Asara JM, Casero RA Jr, et al. Inhibition of the polyamine synthesis enzyme ornithine decarboxylase sensitizes triple-negative breast cancer cells to cytotoxic chemotherapy. J Biol Chem. 2020;295:6263–77. https://doi.org/10.1074/jbc.RA119.012376.CrossRefPubMedPubMedCentral

29.

Granit A, Mishra K, Barasch D, Peretz-Yablonsky T, Eyal S, et al. Metabolomic profiling of triple negative breast cancer cells suggests that valproic acid can enhance the anticancer effect of cisplatin. Front Cell Dev Biol. 2022;10:1014798. https://doi.org/10.3389/fcell.2022.1014798.CrossRefPubMedPubMedCentral

30.

Vojtek M, Martins CB, Ramos R, Duarte SG, Ferreira IMPLVO, et al. Pd(II) and Pt(II) trinuclear chelates with spermidine: selective anticancer activity towards TNBC-sensitive and -resistant to cisplatin. Pharmaceutics. 2023;15:1205. https://doi.org/10.3390/pharmaceutics15041205.CrossRefPubMedPubMedCentral

31.

Asghar J, Latif L, Alexander SPH, Kendall DA. Development of a novel cell-based, In-Cell Western/ERK assay system for the high-throughput screening of agonists acting on the delta-opioid receptor. Front Pharmacol. 2022;13:933356. https://doi.org/10.3389/fphar.2022.933356.CrossRefPubMedPubMedCentral

32.

Yamanaka S, Sato Y, Oikawa D, Goto E, Fukai S, et al. Subquinocin, a small molecule inhibitor of CYLD and USP-family deubiquitinating enzymes, promotes NF-κB signaling. Biochem Biophys Res Commun. 2020;524:1–7. https://doi.org/10.1016/j.bbrc.2019.12.049.CrossRefPubMed

33.

Wu H, Southam AD, Hines A, Viant MR. High-throughput tissue extraction protocol for NMR- and MS-based metabolomics. Anal Biochem. 2008;372:204–12. https://doi.org/10.1016/j.ab.2007.10.002.CrossRefPubMed

34.

Wishart DS, Guo A, Oler E, Wang F, Anjum A, et al. HMDB 5.0: the human metabolome database for 2022. Nucleic Acids Res. 2022;50:622–31. https://doi.org/10.1093/nar/gkab1062.CrossRef

35.

Berben L, Sereika SM, Engberg S. Effect size estimation: methods and examples. Int J Nurs Stud. 2012;49:1039–47. https://doi.org/10.1016/j.ijnurstu.2012.01.015.CrossRefPubMed

36.

Benjamini Y, Hochberg Y. Controlling the false discovery rate: a practical and powerful approach to multiple testing. J R Stat Soc Ser B. 1995;57:289–300. https://doi.org/10.1016/s0166-4328(01)00297-2.CrossRef

37.

Kanehisa M, Goto S. KEGG: kyoto encyclopedia of genes and genomes. Nucleic Acids Res. 2020;28:27–30.CrossRef

38.

Li S, Li Q, Lü J, Zhao Q, Li D, et al. Targeted inhibition of miR-221/222 promotes cell sensitivity to cisplatin in triple-negative breast cancer MDA-MB-231 cells. Front Genet. 2020;10:1278. https://doi.org/10.3389/fgene.2019.01278.CrossRefPubMedPubMedCentral

39.

Zeng D, Liang YK, Xiao YS, Wei XL, Lin HY, et al. Inhibition of Notch1 reverses EMT and chemoresistance to cisplatin via direct downregulation of MCAM in triple-negative breast cancer cells. Int J Cancer. 2020;147:490–504. https://doi.org/10.1002/ijc.32911.CrossRefPubMed

40.

Mi H, Wang X, Wang F, Li L, Zhu M, et al. SNHG15 contributes to cisplatin resistance in breast cancer through sponging miR-381. Onco Targets Ther. 2020;13:657–66. https://doi.org/10.2147/OTT.S223321.CrossRefPubMedPubMedCentral

41.

Guo YJ, Pan WW, Liu SB, Shen ZF, Xu Y, et al. ERK/MAPK signalling pathway and tumorigenesis. Exp Ther Med. 2020;19:1997–2007. https://doi.org/10.3892/etm.2020.8454.CrossRefPubMedPubMedCentral

42.

Arrieta VA, Chen AX, Kane JR, Kang SJ, Kassab C, et al. ERK1/2 phosphorylation predicts survival following anti-PD-1 immunotherapy in recurrent glioblastoma. Nat Cancer. 2021;2:1372–86. https://doi.org/10.1038/s43018-021-00260-2.CrossRefPubMedPubMedCentral

43.

Xia L, Tan S, Zhou Y, Lin J, Wang H, et al. Role of the NFκB-signaling pathway in cancer. Onco Targets Ther. 2018;11:2063–73. https://doi.org/10.2147/OTT.S161109.CrossRefPubMedPubMedCentral

44.

Guerra ÂR, Paulino AF, Castro MM, Oliveira H, Duarte MF, et al. Triple negative breast cancer and breast epithelial cells differentially reprogram glucose and lipid metabolism upon treatment with triterpenic acids. Biomolecules. 2020;10:1163. https://doi.org/10.3390/biom10081163.CrossRefPubMedPubMedCentral

45.

Amend SR, Torga G, Lin KC, Kostecka LG, de Marzo A, et al. Polyploid giant cancer cells: unrecognized actuators of tumorigenesis, metastasis, and resistance. Prostate. 2019;79:1489–97. https://doi.org/10.1002/pros.23877.CrossRefPubMedPubMedCentral

46.

Parekh A, Das S, Parida S, Das CK, Dutta D, et al. Multi-nucleated cells use ROS to induce breast cancer chemo-resistance in vitro and in vivo. Oncogene. 2018;37:4546–61. https://doi.org/10.1038/s41388-018-0272-6.CrossRefPubMed

47.

Qu Y, Zhang L, Rong Z, He T, Zhang S. Number of glioma polyploid giant cancer cells (PGCCs) associated with vasculogenic mimicry formation and tumor grade in human glioma. J Exp Clin Cancer Res. 2013;32:75. https://doi.org/10.1186/1756-9966-32-75.CrossRefPubMedPubMedCentral

48.

Zhang Y, Wu J, Ye M, Wang B, Sheng J, et al. ETS1 is associated with cisplatin resistance through IKKα/NF-κB pathway in cell line MDA-MB-231. Cancer Cell Int. 2018;18:86. https://doi.org/10.1186/s12935-018-0581-4.CrossRefPubMedPubMedCentral

49.

Yeh PY, Yeh KH, Chuang SE, Song YC, Cheng AL. Suppression of MEK/ERK signaling pathway enhances cisplatin-induced NF-kappaB activation by protein phosphatase 4-mediated NF-kappaB p65 Thr dephosphorylation. J Biol Chem. 2004;279:26143–8. https://doi.org/10.1074/jbc.M402362200.CrossRefPubMed

50.

Yeh PY, Chuang SE, Yeh KH, Song YC, Ea CK, et al. Increase of the resistance of human cervical carcinoma cells to cisplatin by inhibition of the MEK to ERK signaling pathway partly via enhancement of anticancer drug-induced NF kappa B activation. Biochem Pharmacol. 2002;63:1423–30. https://doi.org/10.1016/s0006-2952(02)00908-5.CrossRefPubMed

51.

Godwin P, Baird AM, Heavey S, Barr MP, O’Byrne KJ, et al. Targeting nuclear factor-kappa B to overcome resistance to chemotherapy. Front Oncol. 2013;3:120. https://doi.org/10.3389/fonc.2013.00120.CrossRefPubMedPubMedCentral

52.

Acosta-Casique A, Montes-Alvarado JB, Barragán M, Larrauri-Rodríguez KA, Perez-Gonzalez A, et al. ERK activation modulates invasiveness and Reactive Oxygen Species (ROS) production in triple negative breast cancer cell lines. Cell Signal. 2023;101:110487. https://doi.org/10.1016/j.cellsig.2022.110487.CrossRefPubMed

53.

Sun X, Wang M, Wang M, Yu X, Guo J, et al. Metabolic reprogramming in triple-negative breast cancer. Front Oncol. 2020;10:428. https://doi.org/10.3389/fonc.2020.00428.CrossRefPubMedPubMedCentral

54.

Papa S, Choy PM, Bubici C. The ERK and JNK pathways in the regulation of metabolic reprogramming. Oncogene. 2019;38:2223–40. https://doi.org/10.1038/s41388-018-0582-8.CrossRefPubMed

55.

Mauro C, Leow SC, Anso E, Rocha S, Thotakura AK, et al. NF-κB controls energy homeostasis and metabolic adaptation by upregulating mitochondrial respiration. Nat Cell Biol. 2011;13:1272–9. https://doi.org/10.1038/ncb2324.CrossRefPubMedPubMedCentral

56.

Papadaki S, Magklara A. Regulation of metabolic plasticity in cancer stem cells and implications in cancer therapy. Cancers (Basel). 2022;14:5912. https://doi.org/10.3390/cancers14235912.CrossRefPubMed

57.

Nassar D, Blanpain C. Cancer stem cells: basic concepts and therapeutic implications. Annu Rev Pathol. 2016;11:47–76. https://doi.org/10.1146/annurev-pathol-012615-044438.CrossRefPubMed

58.

Nong X, Zhang C, Wang J, Ding P, Ji G, et al. The mechanism of branched-chain amino acid transferases in different diseases: research progress and future prospects. Front Oncol. 2022;12:988290. https://doi.org/10.3389/fonc.2022.988290.CrossRefPubMedPubMedCentral

59.

Luo L, Sun W, Zhu W, Li S, Zhang W, et al. BCAT1 decreases the sensitivity of cancer cells to cisplatin by regulating mTOR-mediated autophagy via branched-chain amino acid metabolism. Cell Death Dis. 2021;12:169. https://doi.org/10.1038/s41419-021-03456-7.CrossRefPubMedPubMedCentral

60.

Zhang L, Bu P. The two sides of creatine in cancer. Trends Cell Biol. 2022;32:380–90. https://doi.org/10.1016/j.tcb.2021.11.004.CrossRefPubMed

61.

Chen HH, Kuo MT. Role of glutathione in the regulation of Cisplatin resistance in cancer chemotherapy. Met Based Drugs. 2010;2010:430939. https://doi.org/10.1155/2010/430939.CrossRefPubMedPubMedCentral

62.

Lingappan K. NF-κB in oxidative stress. Curr Opin Toxicol. 2018;7:81–6. https://doi.org/10.1016/j.cotox.2017.11.002.CrossRefPubMed

63.

Sørensen BH, Thorsteinsdottir UA, Lambert IH. Acquired cisplatin resistance in human ovarian A2780 cancer cells correlates with shift in taurine homeostasis and ability to volume regulate. Am J Physiol Cell Physiol. 2014;307:C1071–80. https://doi.org/10.1152/ajpcell.00274.2014.CrossRefPubMed

64.

Duan M, Ulibarri J, Liu KJ, Mao P. Role of nucleotide excision repair in cisplatin resistance. Int J Mol Sci. 2020;21:9248. https://doi.org/10.3390/ijms21239248.CrossRefPubMedPubMedCentral

65.

Rocha CRR, Silva MM, Quinet A, Cabral-Neto JB, Menck CFM. DNA repair pathways and cisplatin resistance: an intimate relationship. Clinics. 2018;73(Suppl 1):e478s. https://doi.org/10.6061/clinics/2018/e478s.CrossRefPubMedPubMedCentral

66.

Molinaro C, Martoriati A, Cailliau K. Proteins from the DNA damage response: regulation, dysfunction, and anticancer strategies. Cancers (Basel). 2021;13:3819. https://doi.org/10.3390/cancers13153819.CrossRefPubMed

67.

Zong C, Zhu T, He J, Huang R, Jia R, et al. PARP mediated DNA damage response, genomic stability and immune responses. Int J Cancer. 2022;150:1745–59. https://doi.org/10.1002/ijc.33918.CrossRefPubMed

68.

Murata MM, Kong X, Moncada E, Chen Y, Imamura H, et al. NAD⁺ consumption by PARP1 in response to DNA damage triggers metabolic shift critical for damaged cell survival. Mol Biol Cell. 2019;30:2584–97. https://doi.org/10.1091/mbc.E18-10-0650.CrossRefPubMedPubMedCentral

Title: Disclosing a metabolic signature of cisplatin resistance in MDA-MB-231 triple-negative breast cancer cells by NMR metabolomics
Authors: Tatiana J. Carneiro
Ana L. M. Batista Carvalho
Martin Vojtek
Inês F. Carmo
Maria Paula M. Marques
Carmen Diniz
Ana M. Gil
Publication date: 01-12-2023
Publisher: BioMed Central
Keywords: Breast Cancer
Breast Cancer
Published in: Cancer Cell International / Issue 1/2023
Electronic ISSN: 1475-2867
DOI: https://doi.org/10.1186/s12935-023-03124-0

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 1/2023

Circular RNA circEYA3 promotes the radiation resistance of hepatocellular carcinoma via the IGF2BP2/DTX3L axis

A novel Menin-MLL1 inhibitor, DS-1594a, prevents the progression of acute leukemia with rearranged MLL1 or mutated NPM1

Methylmalonic acid promotes colorectal cancer progression via activation of Wnt/β-catenin pathway mediated epithelial–mesenchymal transition

NEDD8 promotes radioresistance via triggering autophagy formation and serves as a novel prognostic marker in oral squamous cell carcinoma

Long non-coding RNA signature in colorectal cancer: research progression and clinical application

The various role of microRNAs in breast cancer angiogenesis, with a special focus on novel miRNA-based delivery strategies

Keynote webinar | Spotlight on antibody–drug conjugates in cancer